JPET

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Schober, D. A.
Right arrow Articles by Gehlert, D. R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Schober, D. A.
Right arrow Articles by Gehlert, D. R.

Vol. 293, Issue 1, 275-280, April 2000

Pharmacological Characterization of 125I-1229U91 Binding to Y1 and Y4 Neuropeptide Y/Peptide YY Receptors

Douglas A. Schober, Susan L. Gackenheimer, Mark L. Heiman and Donald R. Gehlert

Lilly Neuroscience (D.A.S., S.L.G., D.R.G.) and Lilly Endocrine Research (M.L.H.), Lilly Research Laboratories, Eli Lilly and Co., Lilly Corporate Center, Indianapolis, Indiana

1229U91 (GW1229 or GR231118) [lle,Glu,Pro,Dpr,Tyr, Arg,Leu,Arg,Tyr-NH2)2 cyclic (2,4'),(2'4)-diamide] has been reported by several research groups to be a potent antagonist at the Y1 neuropeptide Y (NPY) receptor subtype. However, 1229U91 also displaces 125I-peptide YY (PYY) with high affinity from the Y4 subtype. Previously, we reported that 1229U91 had full agonist properties for the Y4 receptor. To characterize the pharmacological properties of 1229U91 directly, we had it radioiodinated with the chloromine-T method. 125I-1229U91 bound to cell lines expressing the human Y1 and Y4 receptors with high affinity. The Kd and Bmax for 125I-1229U91 binding to Y1 were 14.9 pM and 1458 fmol/mg protein, respectively. The Y4 receptor bound 125I-1229U91 with a Kd of 12.5 pM and a Bmax of 1442 fmol/mg protein. When competing 125I-1229U91 binding from Y1 and Y4 receptors, a similar rank order of potency was observed: 1229U91 > [Leu31,Pro34]-NPY >=  [Leu31,Pro34]-PYY > PYY >=  NPY > NPY(2-36) > PYY(3-36). Pancreatic polypeptide (PP) potently displaced 125I-1229U91 from the Y4 receptor, but displayed little affinity for Y1. In autoradiographic studies with rat brain sections, 125I-1229U91 bound with a distribution similar to that reported for the Y1 receptor when localized with 125I-[Leu31,Pro34]-PYY. Brain regions exhibiting binding sites for 125I-PP were not detected with this radioligand. Those include the interpeduncular nucleus and the periventricular nucleus of the hypothalamus. Furthermore, 125I-labeled rat PP was not displaced from these areas with 10 nM 1229U91. Thus, 125I-1229U91 is a high affinity Y1 and Y4 radioligand and binds with a distribution in the rat brain consistent with the localization of the Y1 receptor.


0022-3565/00/2931-0275$03.00/0
THE JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
Copyright © 2000 by The American Society for Pharmacology and Experimental Therapeutics



This article has been cited by other articles:


Home page
Endocr. Rev.Home page
M. M. Kamiji and A. Inui
Neuropeptide Y Receptor Selective Ligands in the Treatment of Obesity
Endocr. Rev., October 1, 2007; 28(6): 664 - 684.
[Abstract] [Full Text] [PDF]


Home page
J. Pharmacol. Exp. Ther.Home page
I. R. Tough, N. D. Holliday, and H. M. Cox
Y4 Receptors Mediate the Inhibitory Responses of Pancreatic Polypeptide in Human and Mouse Colon Mucosa
J. Pharmacol. Exp. Ther., October 1, 2006; 319(1): 20 - 30.
[Abstract] [Full Text] [PDF]


Home page
J. Pharmacol. Exp. Ther.Home page
Y. Dumont, E. Moyse, A. Fournier, and R. Quirion
Evidence for the Existence of an Additional Class of Neuropeptide Y Receptor Sites in Rat Brain
J. Pharmacol. Exp. Ther., October 1, 2005; 315(1): 99 - 108.
[Abstract] [Full Text] [PDF]


Home page
J. Neurosci.Home page
C. Acuna-Goycolea, N. Tamamaki, Y. Yanagawa, K. Obata, and A. N. van den Pol
Mechanisms of Neuropeptide Y, Peptide YY, and Pancreatic Polypeptide Inhibition of Identified Green Fluorescent Protein-Expressing GABA Neurons in the Hypothalamic Neuroendocrine Arcuate Nucleus
J. Neurosci., August 10, 2005; 25(32): 7406 - 7419.
[Abstract] [Full Text] [PDF]


Home page
Exp. Biol. Med.Home page
M. M. Berglund, P. A. Hipskind, and D. R. Gehlert
Recent Developments in Our Understanding of the Physiological Role of PP-Fold Peptide Receptor Subtypes
Experimental Biology and Medicine, March 1, 2003; 228(3): 217 - 244.
[Abstract] [Full Text] [PDF]


Home page
J. Neurosci.Home page
R. E. Campbell, M. S. Smith, S. E. Allen, B. E. Grayson, J. M. H. ffrench-Mullen, and K. L. Grove
Orexin Neurons Express a Functional Pancreatic Polypeptide Y4 Receptor
J. Neurosci., February 15, 2003; 23(4): 1487 - 1497.
[Abstract] [Full Text] [PDF]




Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 2000 by the American Society for Pharmacology and Experimental Therapeutics.